ClinicalTrials.gg
CompletedNCT06804590Updated Aug 7, 2026

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of 9MW0311 and Prolia® in Postmenopausal Women Osteoporosis, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Completed at 1 site in China. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
14th of 64
280 · median 90
Started
2024
with 4 others
Phase 3
24 of 64
2 open now
Registered
60th of 64
by date

Among the 64 studies testing denosumab in Osteoporosis, this one is the 14th largest by enrollment, is one of 5 that started in 2024, is one of 24 in phase 3, and was the 60th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with osteoporosis at high risk for fracture.

Read the detailed description

278 patients are randomized 1:1 to receive 9MW0311 and Prolia® every 6 months for 12 months. The primary efficacy endpoint is the percentage change from baseline in BMD at the lumbar spine(LS) in month 12.

03

Conditions studied

  • Postmenopausal Women Osteoporosis

Browse trials for

Keywords

  • Denosumab
  • efficacy
  • MW031
  • postmenopausal women
  • safety
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who can walk freely (≥50 and ≤80 years);
  • As measured by DXA, the absolute value of BMD at lumbar spine, femoral neck or total hip was -4.0\<T value ≤-2.5;
  • Subjects must have at least one of the following other risk factors: 1) history of previous fragility fractures; 2) Either or both parents have a history of hip fragility fracture; 3) Increased bone turnover rate during screening; 4) Low body weight; 5) Old age(≥70); 6) Currently smoking.
  • The duration of spontaneous amenorrhea was >2 years or >2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels >40mIU/mL may be used to confirm the status of postoperative menopause.

Exclusion criteria

Exclusion Criteria:

  • Bone/metabolic disease
  • Hyperparathyroidism or hypoparathyroidism
  • Thyroid condition: Hyperthyroidism or hypothyroidism
  • Rheumatoid arthritis
  • Malignant tumors
  • Malabsorption syndrome
  • Liver cirrhosis, active or , and unstable liver disease; serum and alanine aminotransferase ≥ 2.0 times the (ULN); alkaline phosphatase or total ≥ 1.5 ULN;
  • Renal disease - severe impairment of kidney function
  • cardiovascular and cerebrovascular diseases (such as myocardial infarction, unstable angina or stroke, class III or IV heart failure in the 12 months prior to screening) and hematopoietic system disease judged by the investigator;
  • Hypercalcemia or hypocalcemia ;
  • vitamin D deficiency (25-hydroxyvitamin D, 25OHD \<20 ng/mL);
  • Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery;
  • Use of intravenous bisphosphonates within the previous 2 years;
  • oral bisphosphonates (used for at least 2 years, or used for less than 2 years but more than 3 months, with the last use occurring \<1 year before the screening);
  • Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism:

    1. parathyroid hormone (PTH) or PTH derivatives, such as teriparatide;
    2. anabolic hormones or testosterone;
    3. (equivalent dose more than 5mg/ day of prednisone and continuous use for more than 10 days);
    4. Selective estrogen receptor modulators (SERMs), such as raloxifene;
    5. Menopausal hormone therapy (such as estrogen, estrogen + progesterone, tibolone);
    6. Active vitamin D and its analogues (cumulative use of more than 30 days);
    7. Other bone-active drugs include antiepileptic drugs (except benzodiazepines) and heparin;
    8. Long-term systemic use of ketoconazole, adrenocorticotropin (ACTH), aluminum, lithium, protease inhibitors, methotrexate, gonadotropin releasing hormone agonists;
    9. Chinese patent medicines for osteoporosis related treatment are clearly described in the instructions, such as Xianling Gubao capsule (tablet), Gushukang capsule (granule), Jintiange capsule and Qianggu capsule."
  • History of more than two vertebral fractures.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    9MW0311

    9MW0311 Denosumab injection(60 mg)

    Drug: 9MW0311

  • Active comparator
    Prolia®

    Prolia® Denosumab injection(60 mg)

    Drug: Prolia®

Interventions

  • 9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

  • Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in lumbar spine(LS)-BMD at Week 53 (Month 12)

    Percent Change From Baseline in LS-BMD at Week 53 (Month 12)

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Percent Change From Baseline in LS-BMD at Week 27 (Month 6)

    Percent Change From Baseline in LS-BMD at Week 27 (Month 6)

    Time frame: Baseline and Month 6

  2. Percent change in BMD at the total hip, femoral neck from Baseline up to week 27 (Month 6) and Week 53 (Month 12 )

    Percent change in BMD at the total hip, femoral neck from Baseline up to week 27 (Month 6) and Week 53 (Month 12 )

    Time frame: Baseline, Month6 and Month 53

  3. Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum type I procollagen N-terminal propeptide (s-PINP) from Baseline up to 12 months

    Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum type I procollagen N-terminal propeptide (s-PINP) from Baseline up to 12 months

    Time frame: Baseline, Month1, Month3, Month6, Month9 and Month 12

  4. Proportion of subjects with new fragility fractures (e.g., vertebrae, hip, non-vertebrae)

    Proportion of subjects with new fragility fractures (e.g., vertebrae, hip, non-vertebrae)

    Time frame: From baseline to Month12

  5. Number of participants with AE, SAE, with abnormal vital signs, abnormal physical examination findings, abnormal oral examination findings, abnormal laboratory tests results and abnormal 12-lead ECG readings

    AE, SAE, vital signs, physical examination, oral examination, laboratory examination (blood routine, urine routine/urine sediment, blood biochemistry, coagulation function), 12-lead ECG

    Time frame: From baseline to Month12

  6. ADA positive rate and ADA titer (if applicable)

    ADA positive rate and ADA titer (if applicable)

    Time frame: Baseline and Month 1, Month3, Month6, Month12

  7. NAb positive rate (if applicable)

    NAb positive rate (if applicable)

    Time frame: Baseline and Month 1, Month3, Month6, Month12

07

Study locations

1 site
  • Mabwell (Shanghai) Bioscience Co., Ltd.
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2026, 17 months.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 17 months is below that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Feb 3, 2025
StartActual
Nov 16, 2024
Primary completionActual
Apr 24, 2026
CompletionActual
Jun 30, 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06804590
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Nov 16, 2024
Primary completion
Apr 24, 2026
Completion
Jun 30, 2026
Last update
Aug 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion